Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

Open Antibody Sourcing

Open Antibody SourcingOpen Antibody Sourcing
What we are looking for
We seek an antibody against a tumor-specific target in humans. The target should be expressed on the surface of human cancer cells. The epitope recognized by the antibody can be a peptide sequence, a sugar moiety, a lipid or a mixture of these. The antibody can be monospecific or bi-(or multi-)specific. The antibody should show no or little binding to normal healthy human tissue by being directed against a target that is expressed on tumor cells, but not or to a much lesser extent in normal tissue. This can also include a bispecific approach against two non-tumor specific targets that are co-expressed in tumor tissue, but not in normal tissue. The antibody can be at early stage (i.e. requiring further engineering and optimization). Ideally, the antibody is cross-reactive to rodent species to facilitate early safety studies. However, lack of such cross-reactivity is not an exclusion criterion per se. The antibody candidate should have good internalization properties or should at least have a clear potential to be tailored in this direction.
Open Antibody Sourcing

What we expect in your submission
We at EMD Serono do have a good understanding of existing technologies for antibody-drug conjugates, suitable targets and available antibodies.
We are only interested in proposals for antibodies that are available for licensing, including full IP rights and exclusive rights for the development and usage of the antibody as an antibody-drug conjugate and for diagnostic purposes.
Proposals from a wide range of academic as well as non-academic institutions, from start-ups as well as small and medium-sized enterprises (SMEs) are envisioned. You yourself do not need to have experience in antibody drug conjugate technologies, but your proposed antibody should have a good selectivity for the tumor-specific antigen/target. You also should be in the legal position to offer the antibody to us for further clinical use and development.
What to submit
Your proposal should include the following information:
  1. Collaboration Proposal:
    a) A description and proof for the tumor specificity of the antibody/antibodies offered. You can withhold proprietary information, if necessary, but should provide enough information to us to appreciate the merits of your approach.
    b) A brief discussion of capabilities and prior experience as relevant to the problem including any publications or citations, as appropriate. You should explain what you can provide and what might be required from our side. For example: “I can provide samples, but I would need you to run the testing”
  2. General Information:
    a) Organization/Company/University name and address
    b) The key contact person (including phone number and email address). 

What we offer
Your proposal should contain non-confidential information only. All proposals will be evaluated and assessed in our R&D organization. If your proposal is interesting for us, we will get back to you within 4 weeks to discuss next steps towards a licensing agreement.
How to submit
Send your proposal to
This program is not open to U.S. healthcare professionals.


Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.


Submit your application to:
Register for our mailing list:
Register now!
Read more on M - The Explorer Magazine

Free-form displays in the cockpit

What was once known as the dashboard can now justifiably be called a cockpit: Our innovations for LC displays are opening up new dimensions that will also benefit automobile designers.

Read more on M - The Explorer Magazine
Read more on M - The Explorer Magazine

More safety: Smart automotive lighting

In cooperation with industrial partners such as Hella and Porsche, we are developing a headlight system that will improve traffic safety – thanks to liquid crystals shutters for sensitive responding.

Read more on M - The Explorer Magazine